Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F19%3A00078737" target="_blank" >RIV/00023001:_____/19:00078737 - isvavai.cz</a>

Result on the web

<a href="https://www.dovepress.com/elbasvirgrazoprevir-in-women-with-hepatitis-c-virus-infection-taking-o-peer-reviewed-fulltext-article-IJWH" target="_blank" >https://www.dovepress.com/elbasvirgrazoprevir-in-women-with-hepatitis-c-virus-infection-taking-o-peer-reviewed-fulltext-article-IJWH</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2147/IJWH.S203022" target="_blank" >10.2147/IJWH.S203022</a>

Result language

angličtina

Original language name

Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy

Original language description

Introduction: Some direct-acting antiviral regimens for hepatitis C virus (HCV) infection pose safety or efficacy concerns if coadministered with drugs containing ethinyl estradiol. The present analysis was conducted to examine the impact of concomitant oral contraceptive pills (OCP) or hormone replacement therapy (HRT) during treatment with elbasvir (EBR)/grazo-previr (GZR) in women with HCV genotype (GT)1 or GT4 infection. Methods: This is a post hoc, integrated retrospective analysis of female participants with HCV GT1 or GT4 infection who received EBR 50 mg/GZR 100 mg once daily for 12 weeks in phase 2/3 clinical trials. The primary end point was sustained virologic response at 12 weeks after therapy completion (SVR12). For this analysis, participants were stratified according to whether they received OCP or HRT during the original treatment study. Results: A total of 1,022 women with HCV GT1 or GT4 infection were included (receiving OCP/HRT, n=81; not receiving OCP/HRT, n=941). Most participants receiving OCP/HRT were treatment-naive (79%), noncirrhotic (91.4%), and aged &gt;35 years (71.6%). SVR12 rates were similar in women receiving OCP/HRT and those not receiving OCP/HRT (95.1% vs 96.3%). SVR12 rates remained high across all subgroups within the population receiving OCP/HRT: SVR12 rates were 94.6%, 100%, and 100% in participants with GT1a, GT1b, and GT4 infection, and all women aged 18–35 years achieved SVR (21/21). Treatment-related adverse events occurred in 40.7% (33/81) and 30.1% (283/941) of women receiving and those not receiving OCP/HRT, respectively. Conclusion: The efficacy and safety of EBR/GZR administered for 12 weeks was similar in women receiving OCP/HRT and those not on OCP/HRT. These data indicate that EBR/GZR can be safely used for the treatment of HCV GT1 or GT4 infection in women receiving concomitant OCP/HRT. © 2019 Hézode et al.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30214 - Obstetrics and gynaecology

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

International journal of women&apos;s health

ISSN

1179-1411

e-ISSN

—

Volume of the periodical

11

Issue of the periodical within the volume

20 November

Country of publishing house

NZ - NEW ZEALAND

Number of pages

12

Pages from-to

617-628

UT code for WoS article

000503965000001

EID of the result in the Scopus database

2-s2.0-85075287330